A. Karthic

Mr. A. Karthic

Amity University, Mumbai, Mumbai, India
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 December 2020 in Environmental Engineering Research
Verified
Journal Article
Open access
PDF file
APAditya Amrut Pawar
Aditya Amrut Pawar
AKA. Karthic
A. Karthic
SLSangmin Lee
Sangmin Lee
Soumya PanditSoumya Pandit
Soumya Pandit
Sokhee Philemon JungSokhee Philemon Jung
Sokhee Philemon Jung
Anaerobic digestion is a traditional method of producing methane-containing biogas by utilizing the methanogenic conversion of organic matter like agricultural waste and animal excreta. Recently, the application of microbial electrolysis cell (MECs) technology to a traditional anaerobic digestion system has been extensively studied to find new opportunities in increasing wastewater treatability and methane yield and producing valuable chemicals. The finding that both anodic and cathodic bacteria can synthesize methane has led to the efforts of optimizing multiple aspects like microbial species, formation of biofilms, substrate sources and electrode surface for higher production of the combustible compound. MECs are very fascinating because of its ability to uptake a wide variety of raw materials including untreated wastewater (and its microbial content as biocatalysts). Extensive work in this field has established different systems of MECs for hydrogen production and biodegradation of organic compounds. This review is dedicated to explaining the operating principles and mechanism of the MECs for electromethanogenesis using different biochemical pathways. Emphasis on single- and double-chambered MECs along with reactor components is provided for a comprehensive description of the technology. Methane production using hydrogen evolution reaction and nanocatalysts has also been discussed.

6 November 2020 in Journal of Biomolecular Structure and Dynamics
Verified
Journal Article
Closed access
YBYashoda H. Barage
Yashoda H. Barage
AKA. Karthic
A. Karthic
RBRohit Bavi
Rohit Bavi
NDNeetin Desai
Neetin Desai
RKRaj Kumar
Raj Kumar
KLKeun Woo Lee
Keun Woo Lee
The World Health Organization has declared COVID-19 as a global health emergency. COVID-19 is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and highlights an urgent need for therapeutics. Here, we have employed a series of computer-aided drug repurposing campaign to discover inhibitors of RNA dependent RNA polymerase (RdRp) and Nsp15/EndoU. Subsequently, MD simulation has been performed to observe dynamic behavior of identified leads at the active site of RdRp and Nsp15. We successfully identified novel lead molecule such as Alectinib for RdRp while Naldemedine and Ergotamine for NSP15. These lead molecules were accommodated in the active site of the enzyme and stabilized by the networks of the hydrogen bond, pi type and hydrophobic interaction with key residues of either target. Interestingly, identified compounds show molecular mimicry in terms of molecular interactions with key residues of RdRp and Nsp15 essential for catalysis and substrate interaction. Previously, Alectinib, Naldemedine and Ergotamine were used as drug in different diseases might be repurposed against selected protein targets of COVID19. Finally, we propose that the identified inhibitors represent a novel lead molecule to design a more effective inhibitor to stop the progress of pathogen. Communicated by Ramaswamy H. Sarma

1 January 2020
Verified
Book Chapter
Closed access
PDF file
AKA. Karthic
A. Karthic
SPSoumya Pandit
Soumya Pandit
SKSantimoy Khilari
Santimoy Khilari
AMAbhilasha Singh Mathuriya
Abhilasha Singh Mathuriya
Sokhee Philemon JungSokhee Philemon Jung
Sokhee Philemon Jung

26 January 2022 in Molecules
Verified
Journal Article
Open access
PDF file
AKA. Karthic
A. Karthic
Veerbhan kesarwaniVeerbhan kesarwani
Veerbhan kesarwani
RSRahul Kunwar Singh
Rahul Kunwar Singh
PYPavan Kumar Yadav
Pavan Kumar Yadav
Navaneet ChaturvediNavaneet Chaturvedi
Navaneet Chaturvedi
SKSandeep Kushwaha
Sandeep Kushwaha
The human population is still facing appalling conditions due to several outbreaks of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) virus. The absence of specific drugs, appropriate vaccines for mutants, and knowledge of potential therapeutic agents makes this situation more difficult. Several 1, 2, 4-triazolo [1, 5-a] pyrimidine (TP)-derivative compounds were comprehensively studied for antiviral activities against RNA polymerase of HIV, HCV, and influenza viruses, and showed immense pharmacological interest. Therefore, TP-derivative compounds can be repurposed against the RNA-dependent RNA polymerase (RdRp) protein of SARS-CoV-2. In this study, a meta-analysis was performed to ensure the genomic variability and stability of the SARS-CoV-2 RdRp protein. The molecular docking of natural and synthetic TP compounds to RdRp and molecular dynamic (MD) simulations were performed to analyse the dynamic behaviour of TP compounds at the active site of the RdRp protein. TP compounds were also docked against other non-structural proteins (NSP1, NSP2, NSP3, NSP5, NSP8, NSP13, and NSP15) of SARS-CoV-2. Furthermore, the inhibition potential of TP compounds was compared with Remdesivir and Favipiravir drugs as a positive control. Additionally, TP compounds were analysed for inhibitory activity against SARS-CoV RdRp protein. This study demonstrates that TP analogues (monomethylated triazolopyrimidine and essramycin) represent potential lead molecules for designing an effective inhibitor to control viral replication. Furthermore, in vitro and in vivo studies will strengthen the use of these inhibitors as suitable drug candidates against SARS-CoV-2.

29 September 2023 in Indonesian Journal of Biotechnology
Verified
Journal Article
Open access
PDF file
CDChaitali Dhande
Chaitali Dhande
DMDevanshi Mistry
Devanshi Mistry
AKA. Karthic
A. Karthic
RSRajshri Singh
Rajshri Singh
YBYashoda H. Barage
Yashoda H. Barage
Mycobacterium tuberculosis causes tuberculosis (TB), which is a common but life‐debilitating disease. The continued development of resistance to frontline anti‐TB drugs such as isoniazid and rifampicin threatens the efficacy of currently available treatment procedures. This highlights the need to explore diverse approaches essential for drug development against multi‐drug‐resistant strains of tuberculosis. Drug development relies on the findings associated with novel protein targets, which play a crucial role in the disease life cycle. DprE1, an enzyme that plays a critical role in the cell wall synthesis of M. tuberculosis, has been recognized as a promising target for drug development. In the present study, based on previous experimental findings, seven mutant models of DprE1 involved in DprE1 resistance are predicted using homology modeling. Further, potential inhibitors are selected based on their efficacy and IC50 values. Shortlisted inhibitors are docked with the wild‐type and mutant structures of DprE1. The deduced inhibitor molecule (ZINC5) is found to possess high potential as a lead inhibitor for all the models of DprE1. It can be used to circumvent drug resistance in the current treatment regime.

1 January 2021
Verified
Book Chapter
Closed access
AKA. Karthic
A. Karthic
NWNilesh S. Wagh
Nilesh S. Wagh
JLJaya R. Lakkakula
Jaya R. Lakkakula